Skip to content

You are reading 1 of 2 free-access articles allowed for 30 days

Evidence-based approaches to hypertension

A comparison of current European and US guidelines and management principles

An estimated 1.13 billion people worldwide have hypertension. It is a major cardiovascular risk factor and a leading risk factor for global deaths. According to the World Health Organisation (WHO), in 2015, one-in-four men and one-in-five women had hypertension and fewer than one-in-five people with hypertension have the problem under control. The harmful use of alcohol, being overweight and obese, physical inactivity, and high salt intake all contribute to the incidence of hypertension.

Hypertension is not an inevitable consequence of ageing, but once it develops it often requires costly, life-long treatment with medicines. If left uncontrolled, hypertension can cause stroke, myocardial infarction, cardiac failure, dementia, renal failure and blindness. However, most of the known risk factors for raised blood pressure (BP) are modifiable.

WHO defines hypertension as a systolic and/or diastolic BP of ≥140/90mmHg.


The European Society of Cardiology (ESC)/European Society of Hypertension (ESH) define normal blood pressure systolic blood pressure (SBP) as 120-129 and diastolic blood pressure (DBP) as 80-84mm of Hg, high-normal as SBP 130-139 and/or DBP as 85-89mmHg. Grade 1 hypertension as SBP values of 140-159 and/or DBP 90-99mmHg; Grade 2, SBP 140-159 and/or DBP 100-109mmHg; and Grade 3 SBP ≥180 and/or DBP ≥110mmHg.

The American College of Cardiology (ACC) and American Heart Association (AHA) define a new low for hypertension and categorise hypertension as normal, elevated, or stages 1 or 2 hypertension to prevent and treat high BP. Normal BP is defined as <120/<80mmHg; elevated BP 120-129/<80mmHg; hypertension stage 1 is 130-139 or 80-89mmHg; and hypertension stage 2 is ≥140 or ≥90mmHg. They fully endorse the evidence of benefit for a lower systolic BP target than that currently recommended, as documented in the Systolic Blood Pressure Intervention Trial (SPRINT).

The lowering of threshold for diagnosis of hypertension, as recommended by the current ACC/AHA guidelines, a shift that inevitably leads to define more subjects as hypertensive, may be considered in the light of evidence that a higher BP is associated with adverse CV outcomes, even at levels below 140/90mmHg. Other studies have shown that pre-stage hypertension (systolic BP 130-139 and/or diastolic BP 85–89mmHg) was associated with an increased risk of cerebrovascular death compared with normal BP (systolic BP <120 and diastolic BP <80mmHg). Studies have also shown that a greater reduction in systolic BP was associated with a greater risk reduction for cardiovascular events.

Prior to labelling a person with hypertension, it is important to use an average based on ≥2 readings obtained on ≥2 occasions to estimate the individual’s level of BP. The ESC/ESH and US guidelines both suggest regular use of home BP monitoring and ambulatory BP monitoring as an option to confirm the diagnosis of hypertension, detect white-coat and masked hypertension, and monitor BP control for medication adjustment.

As per US guidelines, corresponding BPs are: Office/clinic ≥130/80, home blood pressure monitor (HBPM)≥ 130/80, daytime ambulatory blood pressure monitor (ABPM) ≥130/80, night-time ABPM ≥110/65, and 24-hour ABPM ≥125/75mmHg. In adults with an SBP >130 but <160mmHg or diastolic DBP >80 but <100mmHg, it is reasonable to screen for the presence of white-coat hypertension using either daytime ABPM or HBPM. According to ESC/EHA guidelines, corresponding BPs are: Office/clinic ≥140/90, HBPM ≥135/85, daytime ABPM≥135/85, night-time ABPM ≥120/75, and 24-hour ABPM ≥130/80mmHg.


Recommendations for evaluation of secondary causes of hypertension (Diagram 1), resistant hypertension (Figure 3), and suggested drug approaches are very similar for American and European guidelines. Screening for secondary causes of hypertension is necessary for new-onset or uncontrolled hypertension in adults, including drug-resistant (≥3 drugs), abrupt-onset, age <30 years, excessive target organ damage — cerebral vascular disease, retinopathy, left ventricular hypertrophy, heart failure (HF) with preserved ejection fraction (HFpEF) and HF with reduced EF (HFrEF), coronary artery disease (CAD), chronic kidney disease (CKD), peripheral artery disease, albuminuria or for onset of diastolic hypertension in older adults or in the presence of unprovoked or excessive hypokalaemia. Screening includes testing for CKD, renovascular disease, primary aldosteronism, obstructive sleep apnoea, drug-induced hypertension (non-steroidal anti-inflammatory drugs (NSAIDs), steroids/androgens, decongestants, caffeine, monoamine oxidase inhibitors), and alcohol-induced hypertension. If more specific clinical characteristics are present, screening for uncommon causes of secondary hypertension is indicated (pheochromocytoma, Cushing’s syndrome, congenital adrenal hyperplasia, hypothyroidism, hyperthyroidism, and aortic coarctation).


Similar lifestyle interventions are recommended in both European and American guidelines. Non-pharmacologic interventions to reduce BP include weight loss for overweight or obese patients with a heart-healthy diet, sodium restriction and potassium supplementation within the diet, and increased physical activity.

US guidelines recommend use of BP-lowering medication for primary prevention of cardiovascular disease (CVD) in adults with no history of CVD and with an estimated 10-year atherosclerotic CVD (ASCVD) risk <10 per cent and a SBP ≥140mmHg or a DBP ≥90mmHg. BP-lowering medication is recommended for secondary prevention of recurrent CVD events in patients with CVD and stage 1 hypertension or threshold of SBP 130mmHg or DBP of 80mmHg, and the same threshold for primary prevention in adults whose 10-year atherosclerotic CVD (ASCVD) risk is estimated at 10 per cent or higher (Diagram 2).

European guidelines suggest considering drug treatment in only very high-risk patients with CVD (especially CAD) with BP 130-139/85-89mmHg. However, drug treatment is suggested at that threshold in low-to-moderate risk without CVD, renal disease, or target organ damage if after three-to-six months of lifestyle intervention, BP is not controlled.

Treatment targets

Treatment targets slightly differ in the two guidelines. The 2017 ACC/AHA Guidelines recommend a systolic BP target <130mmHg in almost all hypertensive patients. The strategy is to first follow standard treatment guidelines for coronary artery disease, HFrEF, previous MI, and stable angina, with the addition of other drugs as needed to further control BP.

ESC/ESH Guidelines state that BP should be lowered to levels <140/90mmHg in all patients (I A recommendation) and to ≤130/80mmHg ‘in most patients’, provided that the treatment is ‘well tolerated’ (IA recommendation). Nevertheless, the European guidelines recommend that systolic BP should be lowered (1) to <140mmHg, but not to <130mmHg, in patients aged ≥65 years and (2) <130mmHg, but not below 120mmHg in younger patients (<65 years; I A recommendation)

Recommendations in special situations such as patients with diabetes, CKD, CAD, and stroke/transient ischaemic attack (TIA). The European target in hypertension in diabetes, CAD, and stroke/TIA is SBP 120-130/70-79mmHg for 18-65-year-olds, and 130-139/70-79 for 65 to >80-year-olds. In CKD, the target is <140 to 130mmHg, if tolerated.

In the US, the BP goal for hypertension, diabetes, CAD, and CKD is <130/80mmHg, as tolerated. In those with stage 3 or higher CKD or stage 1 or 2 CKD with albuminuria (>300mg/day), treatment with an angiotensin-converting enzyme (ACE) inhibitor is reasonable to slow progression of kidney disease. An angiotensin receptor blocker (ARB) is reasonable if an ACE inhibitor is not tolerated. In diabetes mellitus (DM) and hypertension, antihypertensive drug treatment should be initiated at a BP ≥130/80mmHg with a treatment goal of <130/80mmHg. In adults with DM and hypertension, all first-line classes of antihypertensive agents (ie, diuretics, ACE inhibitors, ARBs, and calcium channel blockers [CCBs]) are useful and effective. ACE inhibitors or ARBs may be considered in the presence of albuminuria. In patients with aortic disease, beta-blockers are recommended as the preferred antihypertensive drug class in patients with hypertension and thoracic aortic disease.

Patients of African descent, adults with hypertension but without HF or CKD, including those with DM, initial antihypertensive treatment should include a thiazide-type diuretic or CCB. Two or more antihypertensive medications are recommended to achieve a BP target of <130/80mmHg in most adults. In adults with acute intracranial haemorrhage, immediate lowering of SBP to <140mmHg from 150-220mmHg is not of benefit to reduce death, and may cause harm.

Initial first-line therapy includes thiazide diuretics, CCBs, and ACE inhibitors or ARBs. Initial single-pill therapy is the approach in patients with >20/10mmHg above BP goals in US and ≥140/90mmHg in European guidelines. Two first-line drugs of different classes are recommended with stage 2 hypertension in the US and dual combination or triple combination in grade 1 hypertension or above in the European guidelines (Figure 1, 2). Improved adherence can be achieved with once-daily drug dosing, rather than multiple dosing, and with combination therapy rather than administration of the free individual components.

Principles of therapy: ACE inhibitors, ARBs, and direct renin inhibitors should not be used in combination. ACE inhibitors and ARBs increase the risk of hyperkalaemia in CKD and with supplemental K+ or K+-sparing drugs. ACE inhibitors and ARBs should be discontinued during pregnancy. Calcium channel blocker (CCB) dihydropyridines cause oedema and should be avoided in HFrEF.

Loop diuretics are preferred in heart failure and when glomerular filtration rate (GFR) is <30 ml/min. Potassium-sparing diuretics can be used with thiazides in adults with low serum K+, but should be avoided with GFR <45 ml/min.

Spironolactone or eplerenone is preferred for the treatment of primary aldosteronism and in resistant hypertension (Figure 3). Beta-blockers are not first-line therapy, except in CAD and HFrEF. Abrupt cessation of beta-blockers should be avoided. Bisoprolol and metoprolol succinate are preferred in hypertension with HFrEF and bisoprolol when needed for hypertension in the setting of bronchospastic airway disease. Beta-blockers with both alpha- and beta-receptor activity, such as carvedilol, are preferred in HFrEF. Alpha-1 blockers are associated with orthostatic hypotension; this drug class may be considered in men with symptoms of benign prostatic hyperplasia. Central-acting alpha2-agonists should be avoided, and are reserved as last-line due to side-effects and the need to avoid sudden discontinuation.

In summary

The use of 130/80mmHg as a diagnostic threshold and management goal of BP may contribute to more sustained target organ protection and CV disease prevention. Instead of fixing rigid BP targets, what should be pursued in daily practice is an optimal balance between the magnitude of achieved BP reduction and the tolerability of treatment in the single patient.

Every adult with hypertension should have a clear, detailed, and current evidence-based plan of care that ensures the achievement of treatment and self-management goals, effective management of comorbid conditions and timely follow-up with the healthcare team.

References on request

Leave a Comment

You must be logged in to post a comment.

Related on the site

ICGP asks public for ‘patience’ in making vaccination appointments

Apr 16, 2021

GPs advised to ‘store’ AstraZeneca vaccine pending further updates

Apr 15, 2021

IPC inspection reports published by HIQA

Apr 15, 2021

Devastating impact of gender inequality highlighted in new report

Apr 14, 2021

Scroll To Top